What is Pomalidomide?

Category: Prescription Drugs

Most popular types: Pomalyst

false

See also: Pomalidomide-dexamethasone

Pomalidomide is an oral medication that is used for the treatment of multiple myeloma. It is specifically intended for use in patients who have already been treated with lenalidomide and bortezomib and whose disease progressed after completing therapy.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 2
Moderate 8
Mild 6
None 1

Commonly reported side effects and conditions associated with Pomalidomide

Side effect Patients
Fatigue 6
Dizziness 2
Neuropathy 2
Bruising 1
Chronic fatigue 1
Constipation 1

Show all 20 reported side effects

Dosages

Based on patients currently taking Pomalidomide

Dosage Patients
2 mg daily 3
1 mg daily 1
3 mg daily 1
4 mg daily 1
40 mg weekly 1
42 mg daily 1

Why patients stopped taking Pomalidomide

Multiple reasons could be selected

Reason Patients
Side effects too severe 3
Doctor's advice 2
Course of treatment ended 1
Did not seem to work 1
See all 5 patients who've stopped taking Pomalidomide

Duration

Currently taking Pomalidomide

Duration Patients
6 months - 1 year 1
1 - 2 years 2
2 - 5 years 5

Stopped taking Pomalidomide

Duration Patients
Less than 1 month 1
1 - 6 months 3
1 - 2 years 1
Adherence
Adherence Evaluations
Always 15
Usually 1
Sometimes 1
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 5
A little hard to take 3
Not at all hard to take 9
Cost per month
Cost per month Evaluations
$200+ 1
$100-199 1
$50-99 2
$25-49 5
< $25 3
Not specified 5

What people switch to and from

Patients started taking Pomalidomide after stopping:

Treatment Patients
Lenalidomide (Revlimid) 8
Carfilzomib (Kyprolis) 2
Bortezomib-dexamethasone (Vd) 1
Bortezomib-lenalidomide-dexamethasone (VRd) 1
Carfilzomib-lenalidomide-dexamethasone 1

Patients stopped taking Pomalidomide and switched to:

Treatment Patients
Ixazomib (Ninlaro) 2
Last updated:
There are no evaluations for Pomalidomide.